Biogen’s mid-stage trial results for Alzheimer’s therapy diranersen boosted premarket shares by nearly 9% Thursday.
Biogen (BIIB) climbed approximately 9% in premarket trading after releasing topline data from a Phase 2 trial of diranersen, an experimental Alzheimer’s treatment developed with Ionis Pharmaceuticals (IONS). The results drove investor optimism about the drug’s potential efficacy.
The trial evaluated diranersen’s performance in patients with early-stage Alzheimer’s, though specific data points were not disclosed. Biogen’s prior Alzheimer’s efforts, including the controversial Aduhelm, faced regulatory and commercial challenges, heightening scrutiny of new candidates.
Premarket gains reflected market confidence in the therapy’s prospects, though full trial details and regulatory timelines remain pending.